Most patients with common thyroid cancer survive regardless of treatment

Washington, May 18 (ANI): People with papillary thyroid cancer that has not spread beyond the thyroid gland have positive outcomes regardless of whether they receive treatment within the first year after diagnosis, a new research has shown.

Louise Davies, of Dartmouth Medical School, Hanover, N.H. and Gilbert Welch, both also of Department of Veterans Affairs Medical Center, White River Junction, Vt., and The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, studied cancer cases and individual treatment data from National Cancer Institute registries.

They then tracked cause of death through the National Vital Statistics System.

The researchers identified 35,663 patients with papillary thyroid cancer that had not spread to the lymph nodes or other areas at diagnosis. Of these, 440 (1.2 percent) did not undergo immediate, definitive treatment. Over an average of six years of follow-up, six of these patients died of their cancer.

This was not significantly different from the rate of cancer death among the 35,223 individuals who did undergo treatment (161 over an average of 7.6 years of follow-up).

The 20-year survival rate from cancer was estimated to be 97 percent for those who did not receive treatment and 99 percent for those who did.

"These data help put management decisions about localized papillary thyroid cancer in perspective: papillary thyroid cancers of any size that are confined to the thyroid gland, have no lymph node metastases at presentation and do not show extraglandular extension [reach beyond the thyroid gland] are unlikely to result in death due to the cancer," the authors said.

"Thus, clinicians and patients should feel comfortable considering the option to observe for a year or longer cancers that fall into this category.

"When treatment is elected, the cancers in this category can be managed with either hemithyroidectomy [removal of part of the thyroid] or total thyroidectomy [removal of the complete gland], and the prognosis will be the same," they added.

The study has been reported in the May issue of Archives of Otolaryngology-Head and Neck Surgery, one of the JAMA/Archives journals. (ANI)